JP2020518265A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020518265A5 JP2020518265A5 JP2019560380A JP2019560380A JP2020518265A5 JP 2020518265 A5 JP2020518265 A5 JP 2020518265A5 JP 2019560380 A JP2019560380 A JP 2019560380A JP 2019560380 A JP2019560380 A JP 2019560380A JP 2020518265 A5 JP2020518265 A5 JP 2020518265A5
- Authority
- JP
- Japan
- Prior art keywords
- protein
- vector genome
- vector
- activator
- inhibitor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000013598 vector Substances 0.000 claims description 161
- 108090000623 proteins and genes Proteins 0.000 claims description 82
- 238000000034 method Methods 0.000 claims description 56
- 102000004169 proteins and genes Human genes 0.000 claims description 52
- 210000004027 cell Anatomy 0.000 claims description 49
- 239000003112 inhibitor Substances 0.000 claims description 47
- 239000012190 activator Substances 0.000 claims description 46
- 101710154541 Modulator protein Proteins 0.000 claims description 45
- 102100038132 Endogenous retrovirus group K member 6 Pro protein Human genes 0.000 claims description 39
- 108091005804 Peptidases Proteins 0.000 claims description 32
- 239000004365 Protease Substances 0.000 claims description 32
- 230000014509 gene expression Effects 0.000 claims description 27
- 108010067390 Viral Proteins Proteins 0.000 claims description 26
- 230000010076 replication Effects 0.000 claims description 25
- 210000002845 virion Anatomy 0.000 claims description 25
- 108020004707 nucleic acids Proteins 0.000 claims description 24
- 102000039446 nucleic acids Human genes 0.000 claims description 24
- 150000007523 nucleic acids Chemical class 0.000 claims description 24
- 230000001939 inductive effect Effects 0.000 claims description 22
- 125000000729 N-terminal amino-acid group Chemical group 0.000 claims description 18
- 239000003446 ligand Substances 0.000 claims description 16
- 230000002401 inhibitory effect Effects 0.000 claims description 15
- 102000004389 Ribonucleoproteins Human genes 0.000 claims description 13
- 108010081734 Ribonucleoproteins Proteins 0.000 claims description 13
- 108020005004 Guide RNA Proteins 0.000 claims description 12
- 230000003612 virological effect Effects 0.000 claims description 11
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims description 10
- 239000013603 viral vector Substances 0.000 claims description 9
- 101710091045 Envelope protein Proteins 0.000 claims description 8
- 101710188315 Protein X Proteins 0.000 claims description 8
- 239000000203 mixture Substances 0.000 claims description 8
- 241000700605 Viruses Species 0.000 claims description 7
- 229940079593 drug Drugs 0.000 claims description 7
- 239000003814 drug Substances 0.000 claims description 7
- 101001065501 Escherichia phage MS2 Lysis protein Proteins 0.000 claims description 6
- 101710163270 Nuclease Proteins 0.000 claims description 6
- 239000003795 chemical substances by application Substances 0.000 claims description 6
- 108010013369 Enteropeptidase Proteins 0.000 claims description 5
- 102100029727 Enteropeptidase Human genes 0.000 claims description 5
- 108010074860 Factor Xa Proteins 0.000 claims description 5
- 101710181008 P protein Proteins 0.000 claims description 5
- 101710177166 Phosphoprotein Proteins 0.000 claims description 5
- 108090000190 Thrombin Proteins 0.000 claims description 5
- 238000003776 cleavage reaction Methods 0.000 claims description 5
- 230000007017 scission Effects 0.000 claims description 5
- 229960004072 thrombin Drugs 0.000 claims description 5
- 208000010772 Dog disease Diseases 0.000 claims description 4
- 102100031780 Endonuclease Human genes 0.000 claims description 4
- 108010042407 Endonucleases Proteins 0.000 claims description 4
- 239000000411 inducer Substances 0.000 claims description 4
- 101710085938 Matrix protein Proteins 0.000 claims description 3
- 101710127721 Membrane protein Proteins 0.000 claims description 3
- 102100034574 P protein Human genes 0.000 claims description 3
- 241000711798 Rabies lyssavirus Species 0.000 claims description 3
- 102000018120 Recombinases Human genes 0.000 claims description 3
- 108010091086 Recombinases Proteins 0.000 claims description 3
- 241000607479 Yersinia pestis Species 0.000 claims description 3
- 210000000805 cytoplasm Anatomy 0.000 claims description 3
- 239000003937 drug carrier Substances 0.000 claims description 3
- 238000001476 gene delivery Methods 0.000 claims description 3
- 230000028993 immune response Effects 0.000 claims description 3
- 229960001438 immunostimulant agent Drugs 0.000 claims description 3
- 239000003022 immunostimulating agent Substances 0.000 claims description 3
- 230000003308 immunostimulating effect Effects 0.000 claims description 3
- 239000003550 marker Substances 0.000 claims description 3
- 210000002569 neuron Anatomy 0.000 claims description 3
- 238000004806 packaging method and process Methods 0.000 claims description 3
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 3
- 230000035897 transcription Effects 0.000 claims description 3
- 238000013518 transcription Methods 0.000 claims description 3
- 102000007999 Nuclear Proteins Human genes 0.000 claims description 2
- 108010089610 Nuclear Proteins Proteins 0.000 claims description 2
- 206010037742 Rabies Diseases 0.000 claims description 2
- 108010003533 Viral Envelope Proteins Proteins 0.000 claims description 2
- 102100032965 Myomesin-2 Human genes 0.000 claims 1
- 102000035195 Peptidases Human genes 0.000 claims 1
- 108010015724 Prephenate Dehydratase Proteins 0.000 claims 1
- 230000004913 activation Effects 0.000 claims 1
- 230000005764 inhibitory process Effects 0.000 claims 1
- MCJGNVYPOGVAJF-UHFFFAOYSA-N quinolin-8-ol Chemical compound C1=CN=C2C(O)=CC=CC2=C1 MCJGNVYPOGVAJF-UHFFFAOYSA-N 0.000 claims 1
- 241000711513 Mononegavirales Species 0.000 description 7
- 229930192334 Auxin Natural products 0.000 description 2
- 102000011931 Nucleoproteins Human genes 0.000 description 2
- 108010061100 Nucleoproteins Proteins 0.000 description 2
- 239000002363 auxin Substances 0.000 description 2
- SEOVTRFCIGRIMH-UHFFFAOYSA-N indole-3-acetic acid Chemical compound C1=CC=C2C(CC(=O)O)=CNC2=C1 SEOVTRFCIGRIMH-UHFFFAOYSA-N 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 241000711975 Vesicular stomatitis virus Species 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1706945.1A GB201706945D0 (en) | 2017-05-02 | 2017-05-02 | Self-inactivating viral vector |
| GB1706945.1 | 2017-05-02 | ||
| PCT/GB2018/051166 WO2018203049A1 (en) | 2017-05-02 | 2018-05-02 | Self-inactivating viral vector |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020518265A JP2020518265A (ja) | 2020-06-25 |
| JP2020518265A5 true JP2020518265A5 (https=) | 2021-07-26 |
| JP7420558B2 JP7420558B2 (ja) | 2024-01-23 |
Family
ID=59011153
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019560380A Active JP7420558B2 (ja) | 2017-05-02 | 2018-05-02 | 自己不活性化ウイルスベクター |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US12203092B2 (https=) |
| EP (1) | EP3619314B1 (https=) |
| JP (1) | JP7420558B2 (https=) |
| KR (1) | KR20200015900A (https=) |
| CN (1) | CN110914439B (https=) |
| AU (1) | AU2018262281B2 (https=) |
| BR (1) | BR112019023003A2 (https=) |
| CA (1) | CA3060675A1 (https=) |
| GB (1) | GB201706945D0 (https=) |
| WO (1) | WO2018203049A1 (https=) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2021004389A1 (zh) * | 2019-07-05 | 2021-01-14 | 司龙龙 | 蛋白水解靶向病毒、其活疫苗及其制备方法和用途 |
| CA3208612A1 (en) * | 2021-02-19 | 2022-08-25 | Beam Therapeutics Inc. | Recombinant rabies viruses for gene therapy |
| AU2022264328A1 (en) * | 2021-04-27 | 2023-11-16 | The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. | Recombinant cedar virus chimeras |
| CN115704012A (zh) * | 2021-08-12 | 2023-02-17 | 中国科学院深圳先进技术研究院 | 一种含有降解决定子的重组病毒及其制备方法和应用 |
| CA3230629A1 (en) * | 2021-09-08 | 2023-03-16 | Beam Therapeutics Inc. | Viral guide rna delivery |
| CN116262911B (zh) * | 2021-12-14 | 2026-02-17 | 中国科学院深圳先进技术研究院 | 一种减毒、复制可控的顺向hsv示踪系统及其构建方法和应用 |
| CN114058641B (zh) * | 2022-01-17 | 2022-04-01 | 苏州大学 | 一种载体系统和应用及通过其降解目的蛋白的方法 |
| CN116676273A (zh) * | 2022-02-22 | 2023-09-01 | 中国科学院深圳先进技术研究院 | 一种蛋白水解靶向流感病毒及其制备方法和应用 |
| CN120366391A (zh) * | 2023-04-18 | 2025-07-25 | 上海本导基因技术有限公司 | 一种用于治疗亨廷顿疾病的慢病毒样颗粒 |
| CN117867029B (zh) * | 2023-12-29 | 2024-12-20 | 复百澳(苏州)生物医药科技有限公司 | 一种狂犬亚型假病毒的制备方法及应用 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HUP0500722A2 (hu) * | 2001-07-20 | 2005-11-28 | The University of Georgia Research Foundation, Inc@Á | Attenuált veszettség vírus, a veszettség elleni vakcináláshoz és a központi idegrendszer génterápiájához egy nukleoprotein mutációval a foszforilezés helyén |
| US7608682B2 (en) | 2002-10-30 | 2009-10-27 | Meso Scale Technologies Llc | Substrates of N-end rule ubiquitylation and methods for measuring the ubiquitylation of these substrates |
| US9212359B2 (en) | 2011-06-23 | 2015-12-15 | Sanford Jay Silverman | Systems for induction of gene expression and protein depletion in yeast |
| US20180195085A1 (en) | 2015-02-02 | 2018-07-12 | Id Pharma Co., Ltd. | Improved negative-strand rna viral vector |
| US10550379B2 (en) * | 2015-06-29 | 2020-02-04 | The Board Of Trustees Of The Leland Stanford Junior University | Degron fusion constructs and methods for controlling protein production |
-
2017
- 2017-05-02 GB GBGB1706945.1A patent/GB201706945D0/en not_active Ceased
-
2018
- 2018-05-02 EP EP18723917.3A patent/EP3619314B1/en active Active
- 2018-05-02 US US16/607,980 patent/US12203092B2/en active Active
- 2018-05-02 JP JP2019560380A patent/JP7420558B2/ja active Active
- 2018-05-02 AU AU2018262281A patent/AU2018262281B2/en active Active
- 2018-05-02 CN CN201880029221.8A patent/CN110914439B/zh active Active
- 2018-05-02 BR BR112019023003A patent/BR112019023003A2/pt not_active Application Discontinuation
- 2018-05-02 WO PCT/GB2018/051166 patent/WO2018203049A1/en not_active Ceased
- 2018-05-02 KR KR1020197035530A patent/KR20200015900A/ko not_active Withdrawn
- 2018-05-02 CA CA3060675A patent/CA3060675A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020518265A5 (https=) | ||
| Fields et al. | Nucleotide sequences of influenza virus segments 1 and 3 reveal mosaic structure of a small viral RNA segment | |
| US10570416B2 (en) | TC-83-derived alphavirus vectors, particles and methods | |
| Emonet et al. | Arenavirus reverse genetics: new approaches for the investigation of arenavirus biology and development of antiviral strategies | |
| US9249395B2 (en) | Pestivirus replicons providing an RNA-based viral vector system | |
| TWI769467B (zh) | 用作b型肝炎病毒(hbv)疫苗之自我複製rna分子及其用途 | |
| JPH06504198A (ja) | Ｄｎａ発現系 | |
| WO2008119827A1 (en) | Transreplicase constructs | |
| JP2005508610A (ja) | 異種タンパク質の製造に有用なプラス鎖ｒｎａウイルスゲノムに由来するレプリコン | |
| JP2004501646A5 (https=) | ||
| US12559527B2 (en) | Compositions comprising V2 opt HIV envelopes | |
| Garcı́a-Sastre et al. | Influenza virus vectors | |
| WO2024015803A9 (en) | Encrypted rna and methods of its use | |
| Lundstrom | The Potential of RNA Vaccines for Infectious Diseases and COVID-19 | |
| RU2383621C2 (ru) | Экспрессирующий вектор, кодирующий coronavirus-подобную частицу | |
| US20150359877A1 (en) | Viral Vaccine Vectors | |
| CN110234347A (zh) | 使用了非感染性副粘病毒粒子的传染病疫苗 | |
| JP2024511356A5 (https=) | ||
| Chiu | Developing a DNA Vaccine Based on the Sindbis Virus Replicon | |
| Li et al. | Turning defects into defenses: the potential and challenges of defective viral genome-based antiviral strategies | |
| HK40011813A (en) | Infectious disease vaccine using non-infectious paramyxovirus particle |